砒霜治疗白血病:中西医结合的典范 砒霜治疗白血病:多学科综合治疗研究成果 http://blog.sciencenet.cn/home.php?mod=spaceuid=280034do=blogid=661016 三氧化二砷,俗称砒霜,分子式As2O3,是最具商业价值的砷化合物及主要的砷化学开始物料。它也是最古老的 毒物 之一,无臭无味,外观为白色霜状粉末,故称砒霜。这是经某几种指定的矿物处理过程所产生的高毒性副产品,例如采金矿、高温蒸馏 砷黄铁矿 (毒砂)并冷凝其白烟等。 中文名称:三氧化二砷 英文名称:arsenic trioxide;arsenous acid anhydride 别名: 砒霜 、无水砷酸、 砒 、 白砒 、亚砷 酸酐 国标编号:61007 CAS号:1327-53-3 EINECS号:215-481-4 InChI编码:InChI=1/2As.3O/q2*+3;3*-2 又称:信石 化学式 As2O3 http://baike.baidu.com/view/85920.htm?fromId=4943 全反式维甲酸 ALL-TRANS-RETINOIC ACID http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+302-79-4 全反式维甲酸,也叫做维A酸。其抗肿瘤作用的证实被誉为九十年代国际抗癌药物的三大发现之一,具有很强的诱导分化肿瘤细胞作用,备受国际国内医药界的关注,是目前国内治疗急性早幼粒细胞白血病、骨髓异常增生(白血病前期)尤其是早幼粒细胞白血病的临床首选药物。同时临床显示用于治疗痤疮、扁平苔藓、白斑、多发性寻常疣及其它角化性皮肤病也有显著疗效。 http://baike.baidu.com/view/370038.htm 参考文献: Results: 1 to 4 of 4 1. Transcriptome and proteome analyses of drug interactions with natural products. Fang H. Wang K. Zhang J. Curr. Drug Metab.. 2008;9(10):1038-48 PMID:19075620 2. . Xu RR. Cao F. Liu ZX. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004;24(5):411-4 PMID:15199624 3. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy. Huan SY. Yang CH. Chen YC. Leuk. Lymphoma. 2000;38(3-4):283-93 PMID:10830735 4. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Chen GQ. Zhu J. Shi XG. Ni JH. Zhong HJ. Si GY. Jin XL. Tang W. Li XS. Xong SM. Shen ZX. Sun GL. Ma J. Zhang P. Zhang TD. Gazin C. Naoe T. 陈赛娟 Chen SJ. 王振义 Wang ZY. 陈竺 Chen Z. Blood. 1996;88(3):1052-61 PMID:8704214 Blood. 1996 Aug 1;88(3):1052-61. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Chen GQ , Zhu J , Shi XG , Ni JH , Zhong HJ , Si GY , Jin XL , Tang W , Li XS , Xong SM , Shen ZX , Sun GL , Ma J , Zhang P , Zhang TD , Gazin C , Naoe T , Chen SJ , Wang ZY , Chen Z . Source Shanghai Institute of Hematology, Rui-Jin Hospital, Department of Biophysics, Shanghai Second Medical University, P.R. China. Abstract It has been shown recently in China that arsenic trioxide (As2O3) is a very effective treatment for acute promyelocytic leukemia (APL). APL patients resistant to all-trans retinoic acid (ATRA) and conventional chemotherapy can still respond to AS2O3. In this study, we addressed the possible cellular and molecular mechanisms of this treatment by using NB4 cells as a model. The results show that: (1) As2O3 triggers relatively specific NB4 cell apoptosis at micromolar concentration, as proved by morphology, histogramic related nuclear DNA contents, and DNA gel eletrophoresis. (2) As2O3 does not influence bax, bcl-x, c-myc, and p53 gene expression, but downregulates bcl-2 gene expression at both mRNA and protein levels. (3) As2O3 induces a significant modulation of the PML staining pattern in NB4 cells and HL-60 cells. The micropunctates characteristic of PML-RAR alpha in NB4 cells dissappear after treatment with As2O3, whereas a diffuse PML staining occurs in the perinuclear cytoplasmic region. In addition, a low percentage of untreated NB4 cells exhibits an accumulation of PML positive particles in a compartment of cytoplasm. The percentage of these cells can be significantly increased after As2O3 treatment. A similar PML staining pattern is observed in apoptotic cells. (4) ATRA pretreatment does not influence As2O3-induced apoptosis. These results suggest that induction of cell apoptosis can be one of the mechanisms of the therapeutic effect of As2O3. Moreover, this apoptosis induction occurs independently of the retinoid pathway and may be mediated, at least partly, through the modulation of bcl-2, as well as PML-RAR alpha and/ or PML proteins. PMID:8704214 Free full text The following toggler user interface control may not be accessible. Tab to the next button to revert the control to an accessible version. Destroy user interface control Publication Types, MeSH Terms, Substances Publication Types Research Support, Non-U.S. Gov't MeSH Terms Apoptosis/drug effects* Arsenicals/pharmacology* Arsenicals/therapeutic use Gene Expression Regulation, Leukemic/drug effects* HL-60 Cells/drug effects Humans Leukemia, Promyelocytic, Acute/drug therapy Leukemia, Promyelocytic, Acute/genetics Leukemia, Promyelocytic, Acute/pathology* Lymphoma, Large B-Cell, Diffuse/pathology Medicine, Chinese Traditional Monocytes/drug effects Neoplasm Proteins/biosynthesis* Neoplasm Proteins/genetics Oncogene Proteins, Fusion/biosynthesis* Oncogene Proteins, Fusion/genetics Oxides/pharmacology* Oxides/therapeutic use Proto-Oncogene Proteins/biosynthesis* Proto-Oncogene Proteins/genetics Proto-Oncogene Proteins c-bcl-2 RNA, Messenger/biosynthesis RNA, Neoplasm/biosynthesis Tumor Cells, Cultured/drug effects Substances Arsenicals Neoplasm Proteins Oncogene Proteins, Fusion Oxides Proto-Oncogene Proteins Proto-Oncogene Proteins c-bcl-2 RNA, Messenger RNA, Neoplasm promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein arsenic trioxide The following toggler user interface control may not be accessible. Tab to the next button to revert the control to an accessible version. Destroy user interface control LinkOut - more resources Full Text Sources HighWire - PDF Medical PML Gene - Genetics Home Reference Acute Myeloid Leukemia - MedlinePlus Health Information Molecular Biology Databases ARSENIC TRIOXIDE - HSDB ARSENIC COMPOUNDS - HSDB 检索策略: leukemia and Traditional Chinese medicine and all-trans retinoic acid and arsenic trioxide 检索结果 394篇相关研究论文: http://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmedfrom_uid=8704214 Results: 1 to 20 of 394 请见 pubmed_result.txt Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo Guang-Biao Zhou 1 , 2 , Hui Kang 1 , Lan Wang 1 , 3 , Li Gao 1 , Ping Liu 1 , Jun Xie 2 , Feng-Xiang Zhang 2 , Xiang-Qin Weng 1 , Zhi-Xiang Shen 1 , Jue Chen 1 , Long-Jun Gu 4 , Ming Yan 5 , Dong-Er Zhang 5 , 陈赛娟 Sai-Juan Chen 1 , 3 , 王振义 Zhen-Yi Wang 1 , and 陈竺 Zhu Chen 1 , 3 http://bloodjournal.hematologylibrary.org/content/109/8/3441